We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
To save content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about saving content to .
To save content items to your Kindle, first ensure no-reply@cambridge.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
This collection of essays pays tribute to Nancy Freeman Regalado, a ground-breaking scholar in the field of medieval French literature whose research has always pushed beyond disciplinary boundaries. The articles in the volume reflect the depth and diversity of her scholarship, as well as her collaborations with literary critics, philologists, historians, art historians, musicologists, and vocalists - in France, England, and the United States. Inspired by her most recent work, these twenty-four essays are tied together by a single question, rich in ramifications: how does performance shape our understanding of medieval and pre-modern literature and culture, whether the nature of that performance is visual, linguistic, theatrical, musical, religious, didactic, socio-political, or editorial? The studies presented here invite us to look afresh at the interrelationship of audience, author, text, and artifact, to imagine new ways of conceptualizing the creation, transmission, and reception of medieval literature, music, and art.
EGLAL DOSS-QUINBY is Professor of French at Smith College; ROBERTA L. KRUEGER is Professor of French at Hamilton College; E. JANE BURNS is Professor of Women's Studies and Adjunct Professor of Comparative Literature at the University of North Carolina, Chapel Hill.
Contributors: ANNE AZÉMA, RENATE BLUMENFELD-KOSINSKI, CYNTHIA J. BROWN, ELIZABETH A. R. BROWN, MATILDA TOMARYN BRUCKNER, E. JANE BURNS, ARDIS BUTTERFIELD, KIMBERLEE CAMPBELL, ROBERT L. A. CLARK, MARK CRUSE, KATHRYN A. DUYS, ELIZABETH EMERY, SYLVIA HUOT, MARILYN LAWRENCE, KATHLEEN A. LOYSEN, LAURIE POSTLEWATE, EDWARD H. ROESNER, SAMUEL N. ROSENBERG, LUCY FREEMAN SANDLER, PAMELA SHEINGORN, HELEN SOLTERER, JANE H. M. TAYLOR, EVELYN BIRGE VITZ, LORI J. WALTERS, AND MICHEL ZINK.
All of the sectors analyzed in this volume face the same dual challenge: the invention of new technology and assuring its long-term clinical adoption by customers. These challenges are neither easy nor inexpensive.
For many of the sectors, the technology and the underlying science have encountered the same phenomenon as technology development in other industrial fields – namely, convergence of many skills. Pharmaceutical and biotechnology firms – long accustomed to both random discovery and synthesis of bioactive chemicals or recombination of known active proteins – have added to their discovery strategies genomic and proteomic foundations for drug discovery. These new sciences are just the first steps in the long process of drug development wherein tools such as bioinformatics must be integrated. As companies in the sector pursue new avenues of discovery and development, and as the associated costs spiral ever upward, healthcare systems throughout the world seek to rationalize care and lower overall costs. The industry has two added burdens, therefore: (1) demonstrating the economic advantages of new drugs, thus giving rise to yet another new discipline, pharmacoeconomics; and (2) demonstrating the relative superiority of new drugs over rival products and therapies, thus giving rise to comparative clinical effectiveness.
In this paper two theorems are proved that give a partial answer to a question posed by G. Behrendt and P. Neumann. Firstly, the existence of a group of cardinality ℵ1 with exactly ℵ1 normal subgroups, yet having a subgroup of index 2 with 2ℵ1 normal subgroups, is consistent with ZFC (the Zermelo-Fraenkel axioms for set theory together with the Axiom of Choice). Secondly, the statement “Every metabelian-by-finite group of cardinality ℵ1 has 2ℵ1 normal subgroups” is consistent with ZFC.
Recommend this
Email your librarian or administrator to recommend adding this to your organisation's collection.
